Latest news and press releases about Enanta Pharmaceuticals, Inc. (ENTA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV).
Price
| Price | $12.70 |
| Market Cap | $369M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.65 |
| EV / EBITDA | -8.58 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -61.84% |
| Return on Invested Capital | -23.81% |
| Return on Assets | -21.30% |
| Gross Margin | 98.15% |
| Operating Margin | -89.99% |
| Net Margin | -96.89% |
Related companies: ASMB · AVIR · CRBU · FHTX · IMRX · NAUT · PRLD
Explore sector: Healthcare · Biotechnology
More sections of ENTA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks